美国证券交易委员会（SEC）已正式宣布Coeptis Therapeutics控股公司的S-4注册声明生效，这标志着该公司与Z Squared的合并交易迈出关键一步。随着监管审批的通过，委托书材料已开始向股东寄送，为即将到来的特别股东大会铺平道路。
此次S-4文件的生效意味着合并双方已满足重要监管条件，股东将很快收到包含交易细节、财务数据及投票程序的委托书。若合并顺利通过，两家公司将整合资源，共同拓展细胞疗法领域的商业布局。
市场分析认为，这一进展将显著提升投资者对Coeptis Therapeutics（股票代码：COEP）未来发展的信心。随着委托书寄送程序的启动，合并交易最终结果预计将在近期揭晓。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.